SCHEMBL13675198

SCHEMBL13675198

Cc1ncnc2nc(Nc3ccc(S(N)(=O)=O)cc3)sc12

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.69
CDK1 P06493 1/20 0.62
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
CCNA2 P20248 5/20 0.50
CDK2 P24941 5/20 0.50
GAA P10253 1/20 0.50
CCNA1 P78396 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
IKBKB O14920 1/20 0.46
DKK1 O94907 1/20 0.46
GSK3B P49841 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483368 0.85 EGFR (0.69) EGFRCDK1MEN1KMT2ACCNA2
SCHEMBL14461359 0.81 EGFR (0.65) EGFRCDK1MEN1KMT2ACCNA2
SCHEMBL5134221 0.81 EGFR (1.00) EGFRCDK1MEN1KMT2AKDM4E
SCHEMBL13672688 0.80 EGFR (1.00) EGFRCDK1MEN1KMT2ACCNA2
SCHEMBL13675240 0.79 EGFR (0.79) EGFRCDK1MEN1KMT2A
SCHEMBL13675045 0.79 EGFR (0.74) EGFRCDK1MEN1KMT2ACCNA2
SCHEMBL13675044 0.79 EGFR (0.75) EGFRCDK1CCNA2CDK2CCNA1
SCHEMBL5066710 0.78 EGFR (0.83) EGFRCDK1CCNA2CDK2CCNA1
SCHEMBL5069434 0.77 EGFR (1.00) EGFRCDK1MEN1KMT2ACCNA2
SCHEMBL13672682 0.77 EGFR (1.00) EGFRCDK1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605154-B2 ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-20 US disclosed